World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom.
World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom.
复制标题
DOI：
10.1111/add.15011
复制
发表时间：
2020-09
期刊：
影响因子：
--
通讯作者：
Anton RF
中科院分区：
文献类型：
--
作者：
Witkiewitz K;Heather N;Falk DE;Litten RZ;Hasin DS;Kranzler HR;Mann KF;O'Malley SS;Anton RF
研究世界卫生组织（WHO）的饮酒风险水平降低是否可以实现，与功能改善相关，并在不同初始酒精依赖严重程度的患者中随时间推移保持。多中心随机临床试验的次要数据分析：美国联合收割机研究和英国酒精治疗试验（UKATT）。酒精依赖患者入组联合收割机（n=1383; 68.8%男性），并在UKATT寻求酒精问题治疗（n=742; 74.1%男性）。纳洛酮、阿坎酸或安慰剂，以及联合行为干预或药物管理。UKATT的社会行为网络疗法或动机增强疗法。世卫组织风险水平的降低通过日历方法进行评估。采用酒精依赖量表、利兹依赖问卷和精神疾病诊断和统计手册测量酒精依赖。功能的措施包括酒精相关的后果（饮酒者后果清单和酒精问题问卷），心理健康（简表健康调查）和肝酶测试。治疗最后一个月WHO风险水平降低1级和2级在1年随访时保持不变[联合收割机组aOR（95% CI）降低1级：3.51（2.73，4.29）和UKATT组：2.65（2.32，2.98）]，并与较少的酒精相关后果相关[例如，B（95% CI）1级降低联合收割机：−26.22（−30.62，−21.82）]，心理健康状况更好[例如，B（95% CI）1水平降低UKATT：9.53（7.36，11.73）]，以及γ-谷氨酰转移酶改善[例如，治疗结束时B（95% CI）1级降低UKATT：−89.77（−122.50，−57.04）]，即使是重度酒精依赖患者。当排除戒酒者时，结果相似。世界卫生组织酒精消费风险水平的降低似乎是可以实现的，与更好的运作有关，并在美国和联合王国长期保持下去。
To examine whether World Health Organization (WHO) risk level reductions in drinking were achievable, associated with improved functioning, and maintained over time among patients at varying initial alcohol dependence severity levels. Secondary data analysis of multisite randomized clinical trials: the US COMBINE Study and the UK Alcohol Treatment Trial (UKATT). Individuals with alcohol dependence enrolled in COMBINE (n=1383; 68.8% male) and seeking treatment for alcohol problems in UKATT (n=742; 74.1% male). Naltrexone, acamprosate, or placebo, and combined behavioral intervention or medication management in COMBINE. Social behavior network therapy or motivational enhancement therapy in UKATT. WHO risk level reductions were assessed via calendar method. Alcohol dependence was measured by the Alcohol Dependence Scale, the Leeds Dependence Questionnaire, and the Diagnostic and Statistical Manual of Mental Disorders. Measures of functioning included alcohol-related consequences (Drinker Inventory of Consequences and Alcohol Problems Questionnaire), mental health (Short Form Health Survey), and liver enzyme tests. One- and 2-level reductions in WHO risk levels in the last month of treatment were maintained at the 1-year follow-up [aOR(95% CI) 1-level reduction in COMBINE: 3.51 (2.73, 4.29) and UKATT: 2.65 (2.32, 2.98)] and associated with fewer alcohol-related consequences [e.g., B(95% CI) 1-level reduction COMBINE: −26.22 (−30.62, −21.82)], better mental health [e.g., B(95% CI) 1-level reduction UKATT: 9.53 (7.36, 11.73)], and improvements in γ-glutamyltransferase [e.g., B(95% CI) 1-level reduction UKATT: −89.77 (−122.50, −57.04)] at the end of treatment, even among patients with severe alcohol dependence. Results were similar when abstainers were excluded. Reductions in World Health Organization risk levels for alcohol consumption appear to be achievable, associated with better functioning, and maintained over time in both the United States and the United Kingdom.
登录
查看更多内容
影响因子：
2.8
作者：
Heather, Nick;Adamson, Simon J.;Slegg, Gary P.
通讯作者：
Slegg, Gary P.
影响因子：
3.4
作者：
Kuerbis, Alexis;Morgenstern, Jon;Hail, Lisa
通讯作者：
Hail, Lisa
影响因子：
3.4
作者：
DeMartini, Kelly S.;Devine, Eric G.;O'Malley, Stephanie S.
通讯作者：
O'Malley, Stephanie S.
DOI：
10.1111/acer.12205
发表时间：
2013-12
期刊：
Alcoholism, clinical and experimental research
影响因子：
--
作者：
Hallgren KA;Witkiewitz K
通讯作者：
Witkiewitz K
影响因子：
64.3
作者：
Hasin, Deborah S.;Wall, Melanie;Anton, Raymond
通讯作者：
Anton, Raymond